Dispensary Warehouse continues to onboard licensed cannabis manufacturers, brand owners, and selected non-PBS therapeutic suppliers into its national, pharmacy-led B2B supply and access network powered by SOVRYN™.
The platform is currently operating in a controlled beta phase, with structured supplier onboarding and pharmacy integration underway. A full commercial launch is planned for the upcoming financial year following completion of this staged onboarding process.
SOVRYN™ has been purpose-built to provide compliant suppliers with a direct, professional route into Australia’s independent pharmacy sector while reducing reliance on traditional wholesale intermediaries. By enabling governed direct-to-pharmacy engagement, the platform removes unnecessary margin layers and improves pricing transparency across non-PBS supply chains.
The system integrates AI-assisted compliance workflows, intelligent order routing, predictive supply visibility, and automated reconciliation designed to strengthen governance, operational efficiency, and commercial clarity.
SOVRYN™ operates exclusively within the professional healthcare supply chain and is not consumer-facing.
Market Context: Growth in Non-PBS Categories
Australia has more than 5,900 community pharmacies nationwide, the majority of which are independently owned and operated.
Demand for non-PBS medicines continues to expand across categories including medicinal cannabis, weight management therapies, dermatology, hair loss and men’s health treatments, libido medicines, and emerging peptide-based therapies.
These privately funded, non-PBS prescription categories are reshaping the commercial landscape for independent pharmacies as traditional front-of-store retail margins face increasing pressure.
Suppliers entering these segments require compliant, structured supply pathways that support pricing transparency, governance, and scalable distribution.
SOVRYN™ has been developed to support this shift.
A Pharmacy-Led Access Model
Dispensary Warehouse is not a wholesaler.
It operates as a pharmacy-led supply and access network designed to support compliant market entry, prescribing alignment, and scalable pharmacy distribution.
SOVRYN™ provides governed direct-to-pharmacy ordering supported by AI-enabled compliance oversight and reconciliation systems. Rather than reselling products, Dispensary Warehouse enables structured engagement between approved suppliers and participating independent pharmacies.
Supplier Participation
Approved suppliers may access:
Prescribing network connectivity, including alignment with Prescripta Health
Regulatory and market-entry support
Sponsorship and participation opportunities within a pharmacy-led ecosystem
Optional storage and fulfilment pathways where required
Professional trade visibility through Dispensary Insider
Integration into a coordinated national pharmacy network
Participation remains approval-based and aligned with professional pharmacy standards.
Independent Pharmacy Focus
SOVRYN™ has been developed specifically for Australia’s independent pharmacy sector, supporting operators seeking greater commercial clarity, margin transparency, and accountable supply relationships within non-PBS categories.
International Engagement
The network continues to engage with Australian manufacturers as well as international cannabis and non-PBS suppliers preparing for compliant entry into Australia, including participants from Canada, the United Kingdom, Europe, Thailand and other select markets.
For Suppliers and Manufacturers
Licensed cannabis and non-PBS suppliers seeking participation in the SOVRYN™ network are invited to register interest via the Dispensary Warehouse website.
Shortlisted applicants will be contacted directly to discuss category fit, supply capability, and onboarding requirements as part of the current intake phase..
